NASDAQ · TNXP
Tonix Pharmaceuticals Holding Corp.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TNXP: Nov 09, 2026
Tonix Pharmaceuticals Holding Corp. Common Stock is expected to report earnings on 11/09/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.51. The reported EPS for the same quarter last year was $-3.59.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.51 | $-2.30 | $-2.72 | 3 |
| Dec 2026 | $-2.17 | $-1.76 | $-2.48 | 3 |
| Mar 2027 | $-1.82 | $-1.82 | $-1.82 | 1 |
| Jun 2027 | $-1.67 | $-1.67 | $-1.67 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · MarketBeat · The Motley Fool- Fintel · Oct 26, 7:11 PM EDTCanaccord Genuity Initiates Coverage of Tonix Pharmaceuticals Holding with BuyFintel reports that on October 26, 2026, Canaccord Genuity initiated coverage of Tonix Pharmaceuticals Holding (NASDAQGS:TNXP) (DB:TPM0) with a Buy recommendation.Prior to this rating action, the stock closed at $5.17 on October 23, 2026. This latest close of $5.17 represents a o
- RTTNews · Oct 15, 8:45 AM EDTTonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine Candidate(RTTNews) – Thursday, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that it will present its investigational TNX-801 vaccine platform at the World Vaccine Congress Europe 2026, scheduled for October 19-21 in Amsterdam, Netherlands. Shares rose 4.40%.
- MarketBeat · Sep 11, 10:01 PM EDTTonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial NearsPharma Frenzy: Volatility Ignites Biotech SectorTonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, w
- RTTNews · Sep 8, 11:52 AM EDTTonix Names Englese Chief Commercial Officer To Expand TONMYA Reach(RTTNews) – onix Pharmaceuticals Holding Corp. (TNXP) announced the promotion of Thomas Englese, MBA, to Chief Commercial Officer, effective immediately.
- MarketBeat · Aug 18, 3:01 AM EDTTonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression PipelinePharma Frenzy: Volatility Ignites Biotech SectorTonix Pharmaceuticals (NASDAQ:TNXP) is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executiv
- The Motley Fool · Aug 17, 10:44 AM EDTTonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 11, 7:41 AM EDTTonix Pharma Q2 Net Product Revenue Jumps On TONMYA Sales; Multiple Clinical Catalysts Ahead(RTTNews) – Tonix Pharmaceuticals Holding Corp. (TNXP), a commercial-stage biopharmaceutical company, announced financial results for the quarter ended June 30, 2026, reflecting revenue growth driven mainly by the sales of the TONMYA drug for Fibromyalgia. In addition, the compan
- MarketBeat · Aug 10, 12:04 PM EDTTonix Pharmaceuticals Q2 Earnings Call HighlightsPharma Frenzy: Volatility Ignites Biotech SectorTonix Pharmaceuticals (NASDAQ:TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the firs
- RTTNews · May 12, 6:11 AM EDTTonix Reports 183% Revenue Growth In Q1; Phase 2 Data Of TNX-102 SL Due In 2H 2026(RTTNews) – Tonix Pharmaceutical Holding Corp (TNXP), a biopharmaceutical company, on Monday released its first-quarter financial results, provided business updates on its commercial products, and progress across its drug pipeline.
- Fintel · May 4, 8:04 PM EDTTD Cowen Initiates Coverage of Tonix Pharmaceuticals Holding (TNXP) with Buy RecommendationFintel reports that on May 4, 2026, TD Cowen initiated coverage of Tonix Pharmaceuticals Holding (NasdaqGS:TNXP) with a Buy recommendation. Analyst Price Forecast Suggests 324.35% Upside
- RTTNews · Jan 30, 9:43 AM ESTTonix Highlights Significant Phase 3 RESILIENT Results For TONMYA At Non-Opioid Pain Summit(RTTNews) – Tonix Pharmaceuticals Holding Corp. (TNXP) presented positive Phase 3 RESILIENT data today, showcasing the efficacy of TONMYA (cyclobenzaprine HCl sublingual tablets) in fibromyalgia at the 2026 Non-Opioid Pain Therapeutics Summit in Boston.
- RTTNews · Jan 30, 7:55 AM ESTTonix Presents Positive Phase 3 RESILIENT Data On TONMYA At 2026 Non-Opioid Pain Therapeutics Summit(RTTNews) – Tonix Pharmaceuticals Holding Corp. (TNXP) on Friday said it presented positive results from the Phase 3 RESILIENT study of TONMYA for fibromyalgia at the 2026 Non-Opioid Pain Therapeutics Summit on January 29 in Boston.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Tonix Pharmaceuticals Holding Corp. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.